DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20162834

Evaluation of the anti-inflammatory activity of dipyridamole in acute and chronic experimental models in albino rats

Vishwaprakash M. K., Laveesh M. R., Somashekara S. C.

Abstract


Background: Cyclic nucleotides, particularly cyclic AMP, have an important regulatory role in a variety of inflammatory processes. The concentration of cAMP can be influenced by either inhibition of phosphodiesterase enzyme or by activating adenylate cyclase enzyme. The present study was undertaken to evaluate the anti-inflammatory activity of dipyridamole a selective (PDE6) phosphodiesterase inhibitor; on acute and chronic experimental models in albino rats.

Methods: Anti-inflammatory activity was evaluated by using carrageenan-induced rat hind paw oedema model for assessing acute anti-inflammatory activity. The normal paw volume (0 hour) and the volume of injected paw (3 hour) were measured by using plethysmometer. Assessment of chronic anti-inflammatory activity was carried out using formalin-induced rat paw edema model. The paw volume was measured at 0 hour and on 7th day after injection of formalin by using plethysmometer. The results obtained were compared with the control and the standard anti-inflammatory drug, indomethacin.

Results: The results indicated that dipyridamole has anti-inflammatory action in both acute and chronic inflammatory models. But statistically significant anti-inflammatory action was seen only with the chronic inflammatory model (0.11±0.05 units, p=0.02). Anti-inflammatory activity could be due to inhibition of inflammatory cells and mediators especially histamine, leukotrienes and eicosanoids.

Conclusions: Selective phosphodiesterase inhibitors could be a source of valuable anti-inflammatory drugs, in addition to currently available steroidal and non-steroidal anti-inflammatory agents.


Keywords


Cyclic nucleotides, Phosphodiesterase, Dipyridamole, Indomethacin, Carrageenan, Formalin, Plethysmometer

Full Text:

PDF

References


Smith VB, Spina D, Clive P. Phosphodiesterase inhibitors. British Journal of Pharmacology. 2006;147:252-7.

Theodore J, Torphy. Phosphodiesterase isozymes; molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998;157:351-70.

Moore AR, Willoughby DA. The role of cAMP regulation in controlling inflammation. Clinical and Experimental Immunology. 1995;101:387-9.

Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-48.

Winter CA, Risley EA, Nuss CW. Carrageenan-induced oedema in hind paw of the rats-an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544-7.

Chau TT. Analgesic testing in animal models. In: Pharmacological methods in the control of inflammation. Alan R Liss Inc P. 1989:195-212.

Hall IP. Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br J Clin Pharmac. 1993;35:1-7.

Guptha SK. Drug screening methods. In Preclinical evaluation of new drugs. 2nd Edition. Bengaluru: Jaypee Brothers Medical Publishers (P) Ltd; 2009:480-97.

Greenwald RA. Animal models for evaluation of arthritic drugs. Meth Find Clin Pharmacol. 1991;13:75-83.

Wheeler AH, Cowan A. Neurogenic and tissue mediated components of formalin-induced oedema. Agents Actions. 1991;34:264-9.

Kim HH, Liao JK. Translational therapeutics of Dipyridamole. Arterioscler Thromb Vasc Biol. 2008;28:39-42.